Lenvatinib in combination with Pembrolizumab for advanced or recurrent endometrial cancer – First Line
Lenvatinib in combination with pembrolizumab is in clinical development for the treatment of advanced or recurrent endometrial cancer. Endometrial cancer is the most common form of womb cancer and originates from the lining of the womb (endometrium). The most common symptoms of this cancer are post-menopausal or irregular vaginal bleeding. Standard of care for patients with advanced or recurrent endometrial cancer is chemotherapy; however, there is a need for more effective and tolerable therapies. Lenvatinib is a tyrosine kinase inhibitor (TKI) that targets several different growth factor receptors including vascular endothelial growth factor (VEGFR) and fibroblast growth factor receptors (FGFR). By blocking these receptors, lenvatinib can reduce tumour growth. Pembrolizumab is a humanised monoclonal antibody that binds to the programmed cell death-1 (PD-1) receptor and improves the activity of the immune system to kill cancer cells. If licenced, lenvatinib in combination with pembrolizumab will provide a first line systemic treatment for adults with advanced or recurrent endometrial cancer who have few tolerable therapies available.